CN104945394B - 二氢嘧啶衍生物的晶型 - Google Patents

二氢嘧啶衍生物的晶型 Download PDF

Info

Publication number
CN104945394B
CN104945394B CN201510364423.6A CN201510364423A CN104945394B CN 104945394 B CN104945394 B CN 104945394B CN 201510364423 A CN201510364423 A CN 201510364423A CN 104945394 B CN104945394 B CN 104945394B
Authority
CN
China
Prior art keywords
present
crystal form
crystal formation
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510364423.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104945394A (zh
Inventor
张英俊
任青云
刘辛昌
王超磊
王天明
S·戈尔德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical Co Ltd
Original Assignee
Guangdong HEC Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong HEC Pharmaceutical Co Ltd filed Critical Guangdong HEC Pharmaceutical Co Ltd
Priority to CN201510364423.6A priority Critical patent/CN104945394B/zh
Publication of CN104945394A publication Critical patent/CN104945394A/zh
Application granted granted Critical
Publication of CN104945394B publication Critical patent/CN104945394B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201510364423.6A 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型 Active CN104945394B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510364423.6A CN104945394B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201210369019 2012-09-27
CN2012103690194 2012-09-27
CN2013101170768 2013-04-04
CN201310117076 2013-04-04
CN201310446506.0A CN103724339B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型
CN201510364423.6A CN104945394B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201310446506.0A Division CN103724339B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Publications (2)

Publication Number Publication Date
CN104945394A CN104945394A (zh) 2015-09-30
CN104945394B true CN104945394B (zh) 2017-12-05

Family

ID=50355923

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201510364423.6A Active CN104945394B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型
CN201310445326.0A Pending CN103694234A (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型
CN201310446506.0A Active CN103724339B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201310445326.0A Pending CN103694234A (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型
CN201310446506.0A Active CN103724339B (zh) 2012-09-27 2013-09-26 二氢嘧啶衍生物的晶型

Country Status (20)

Country Link
US (1) US9403814B2 (enExample)
EP (1) EP2900664B1 (enExample)
JP (1) JP6310923B2 (enExample)
KR (1) KR20150060610A (enExample)
CN (3) CN104945394B (enExample)
AU (1) AU2013324779B2 (enExample)
BR (1) BR112015002979B8 (enExample)
CA (1) CA2881260C (enExample)
DK (1) DK2900664T3 (enExample)
ES (1) ES2660642T3 (enExample)
HU (1) HUE037285T2 (enExample)
MX (1) MX362829B (enExample)
MY (1) MY171497A (enExample)
PL (1) PL2900664T3 (enExample)
PT (1) PT2900664T (enExample)
RU (1) RU2646599C2 (enExample)
SG (1) SG11201500145TA (enExample)
TW (1) TWI561520B (enExample)
WO (1) WO2014048355A1 (enExample)
ZA (1) ZA201500290B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1210152A1 (en) * 2012-09-10 2016-04-15 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2017076286A1 (zh) * 2015-11-04 2017-05-11 南京明德新药研发股份有限公司 二氢吡啶并环化合物的晶型、制备方法和中间体
WO2017198201A1 (en) * 2016-05-19 2017-11-23 Sunshine Lake Pharma Co., Ltd. Crystalline form, salt and complex of dihydropyrimidine derivative, and uses thereof in medicine
CN107722109B (zh) * 2016-08-11 2020-12-18 广东东阳光药业有限公司 作为丙型肝炎病毒抑制剂的晶型
US9856232B1 (en) * 2017-06-20 2018-01-02 King Saud University Dihydropyrimidinone derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777606A (zh) * 2003-04-22 2006-05-24 索尔瓦药物有限公司 4－(4－反式－羟基环己基)氨基－2－苯基－7H－吡咯并[2,3d]嘧啶氢甲磺酸盐及其多晶型物
CN101328171A (zh) * 2007-06-18 2008-12-24 张中能 一种溴苯基-取代的噻唑二氢嘧啶
CN101744823A (zh) * 2008-12-17 2010-06-23 张中能 一种二氢嘧啶类化合物的固体分散体及其药用制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101328170B (zh) 2007-06-18 2011-09-14 张中能 一种氟苯基-取代噻唑二氢嘧啶
CN101328168B (zh) 2007-06-18 2011-09-07 张中能 一种乙氧碳酰基-取代噻唑二氢嘧啶
WO2008154819A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
WO2010069147A1 (zh) * 2008-12-17 2010-06-24 张中能 二氢嘧啶类化合物、其组合物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1777606A (zh) * 2003-04-22 2006-05-24 索尔瓦药物有限公司 4－(4－反式－羟基环己基)氨基－2－苯基－7H－吡咯并[2,3d]嘧啶氢甲磺酸盐及其多晶型物
CN101328171A (zh) * 2007-06-18 2008-12-24 张中能 一种溴苯基-取代的噻唑二氢嘧啶
CN101744823A (zh) * 2008-12-17 2010-06-23 张中能 一种二氢嘧啶类化合物的固体分散体及其药用制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
可激活并使HBV错配的杂环二氢嘧啶类药物.;饶伟;《国外医学情报》;20050831;第26卷;第9-11页. *
新型二氢嘧啶类化合物的合成及其抗乙型肝炎病毒活性研究.;赵国明等，;《中国科学：生命科学》;20111231;第41卷(第10期);第971-977页. *

Also Published As

Publication number Publication date
US20150239877A1 (en) 2015-08-27
EP2900664A4 (en) 2016-03-09
EP2900664A1 (en) 2015-08-05
MX2015004115A (es) 2016-01-20
DK2900664T3 (en) 2018-02-05
CN103724339A (zh) 2014-04-16
ES2660642T3 (es) 2018-03-23
BR112015002979A2 (pt) 2017-07-04
RU2646599C2 (ru) 2018-03-06
US9403814B2 (en) 2016-08-02
CN103694234A (zh) 2014-04-02
HUE037285T2 (hu) 2018-08-28
TWI561520B (en) 2016-12-11
CA2881260C (en) 2020-10-27
WO2014048355A1 (en) 2014-04-03
BR112015002979B1 (pt) 2020-12-22
PL2900664T3 (pl) 2018-06-29
BR112015002979B8 (pt) 2022-03-03
CN104945394A (zh) 2015-09-30
TW201412732A (zh) 2014-04-01
JP6310923B2 (ja) 2018-04-11
MX362829B (es) 2019-02-14
EP2900664B1 (en) 2017-12-13
JP2015531354A (ja) 2015-11-02
CA2881260A1 (en) 2014-04-03
MY171497A (en) 2019-10-15
ZA201500290B (en) 2016-10-26
PT2900664T (pt) 2018-03-02
HK1207081A1 (en) 2016-01-22
AU2013324779A1 (en) 2015-02-05
SG11201500145TA (en) 2015-02-27
KR20150060610A (ko) 2015-06-03
RU2015114085A (ru) 2016-11-20
CN103724339B (zh) 2015-10-14
AU2013324779B2 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
US10662198B2 (en) Polymorphic form of compound, preparation method and use thereof
WO2020259432A1 (zh) Kras-g12c抑制剂
KR101424013B1 (ko) 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법
CN104945394B (zh) 二氢嘧啶衍生物的晶型
JP5687291B2 (ja) 強力なｈｃｖ阻害剤の結晶塩
CN105859708B (zh) 二氢嘧啶衍生物的盐及其在药物中的应用
JP2014144916A (ja) ２−アシルアミノチアゾール化合物の結晶
EP3197879A1 (en) New bicyclic derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
CN117088837A (zh) 乙烯基吡喃酮类化合物及其在治疗阿尔茨海默病中的应用
TW202334143A (zh) 結晶咪唑并[4,5-b]吡啶化合物、醫藥組合物及彼等治療醫學症狀之用途
KR20130108985A (ko) (6，7-디히드로-2-니트로-5ｈ-이미다졸[2,1-ｂ][1,3]옥사진-6-일)아미드 화합물, 그의 제조방법 및 용도
CN106674294A (zh) 吡喃葡萄糖基衍生物的结晶形式
CN106008277A (zh) 一种新型二甲双胍盐酸盐及其制备方法
CN1064681C (zh) 杂环化合物
TW200526205A (en) Nitrogen-containing heterocyclic compound, and medicine containing such compound as effective ingredient
CN116162089B (zh) 嘧啶基抗病毒化合物的制备与使用方法
CN105308043B (zh) 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
HK1207081B (en) Crystalline forms of dihydropyrimidine derivatives
TW202421127A (zh) ５Ｈ－吡咯并〔２，３－ｄ〕嘧啶－６（７Ｈ）－酮及其鹽體之結晶
WO2015109925A1 (zh) 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
HK40117665A (zh) 环己酮化合物的晶型
WO2013103004A1 (ja) （２ｅ）－３－（１ｈ－インダゾール－３－イル）－ｎ－（３－メトキシフェニル）－ｎ－［３－（メチルスルホニル）プロピル］ブト－２－エンアミドの結晶形
JPH02290878A (ja) ベンゾチエノ（フロ）ピリジン誘導体
TW201011015A (en) New compounds 500

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20180612

Address after: 523808 Songshan Lake Science and Technology Industrial Park, Dongguan, Guangdong (No. 1 Industrial North Road, Hubei Industrial Park, Songshan)

Co-patentee after: Ruyuan Yongxing Technical Service Co.,Ltd.

Patentee after: SUNSHINE LAKE PHARMA Co.,Ltd.

Address before: 523000 Songshan Lake Science and Technology Industrial Park, Dongguan, Guangdong (No. 1 Industrial North Road, Hubei Industrial Park, Songshan)

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20191029

Address after: 523808 Guangdong city of Dongguan province Hubei Songshan Industrial Park Industrial Road No. 1

Patentee after: SUNSHINE LAKE PHARMA Co.,Ltd.

Address before: 523808 Songshan Lake Science and Technology Industrial Park, Dongguan City, Guangdong Province (No. 1 Industrial North Road, Songshan Hubei Industrial Park)

Co-patentee before: Ruyuan Yongxing Technical Service Co.,Ltd.

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Crystal form of dihydropyrimidine derivatives

Effective date of registration: 20200514

Granted publication date: 20171205

Pledgee: Zhongrong International Trust Co.,Ltd.

Pledgor: SUNSHINE LAKE PHARMA Co.,Ltd.

Registration number: Y2020990000464

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20220915

Granted publication date: 20171205

Pledgee: Zhongrong International Trust Co.,Ltd.

Pledgor: SUNSHINE LAKE PHARMA Co.,Ltd.

Registration number: Y2020990000464

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.